AN2 Therapeutics (ANTX) Net Cash Flow (2021 - 2026)

AN2 Therapeutics (ANTX) has 6 years of Net Cash Flow data on file, last reported at $33.5 million in Q1 2026.

• On a quarterly basis, Net Cash Flow rose 2599.7% year-over-year to $33.5 million in Q1 2026; TTM through Mar 2026 was $33.5 million, a 815.8% increase from a year earlier, with the FY2025 full-year figure at -$1.4 million, down 124.72% from the prior year.
• Net Cash Flow for Q1 2026 stood at $33.5 million, up from $1.9 million in the prior quarter.
• Over the last five years, Net Cash Flow for ANTX reached as high as $70.4 million in Q1 2022 and fell as low as -$41.9 million in Q2 2022.
• Historically, Net Cash Flow has averaged $2.4 million across 5 years, with a median of -$510000.0 in 2023.
• Across the five-year window, Net Cash Flow sank 973.22% in 2023 and soared 2599.7% in 2026, its largest moves.
• Year by year, Net Cash Flow stood at -$1.6 million in 2022, then sank by 973.22% to -$17.0 million in 2023, then advanced by 28.56% to -$12.1 million in 2024, then jumped by 115.97% to $1.9 million in 2025, then surged by 1630.96% to $33.5 million in 2026.
• Per Business Quant data, the three most recent Net Cash Flow figures were $33.5 million in Q1 2026, $1.9 million in Q4 2025, and -$217000.0 in Q3 2025.